Levi & Korsinsky, LLP has commenced an investigation of ACADIA
Pharmaceuticals Inc. (NASDAQGS:ACAD) in connection with possible
violations of federal securities laws.
To get more information, click here: http://zlk.9nl.com/acadia-pharmaceuticals-acad.
There is no cost or obligation to you.
On March 11, 2015, the Company announced it would delay submitting a New
Drug Application for its drug Nuplazid. The Company also noted that
Chief Executive Officer Uli Hacksell is retiring. Shares of ACADIA were
down more than 20% on intraday trading the following day.
If you own common stock in ACADIA and wish to obtain additional
information about the investigation, please contact Eduard Korsinsky,
Esq. either via email at ek@zlk.com or
by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/acadia-pharmaceuticals-acad.
Levi & Korsinsky is a national firm with offices in New York, New
Jersey, Connecticut and Washington D.C. The firm’s attorneys have
extensive expertise in prosecuting securities litigation involving
financial fraud, representing investors throughout the nation in
securities and shareholder lawsuits. For more information, please feel
free to contact any of the attorneys listed below. Attorney advertising.
Prior results do not guarantee similar outcomes.
Copyright Business Wire 2015